Nebivolol
beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM
Also known as: bystolic, nebivolol HCl, nebivolol hydrochloride, vasoxen
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Nebivolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 4 molecular targets, including ADRB1, HTR1A and ADRB2. Recorded indications include Hypertensive disorder.
- Approval status: ofp (first approved 2007 by the FDA).
- Drug class: beta-Adrenergic Blocker.
- Mechanism of action: Adrenergic beta-Antagonists.
- Molecular targets: ADRB1, HTR1A, ADRB2 and ADRB3 (4 listed in DrugCentral).
- Indications: Hypertensive disorder.
- ATC code: C07AB12 (Beta blocking agents, selective).
- Molecular formula: C22H25F2NO4; molecular weight 405.44 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Off-label uses (4)
- Angina pectoris
- Atrial fibrillation
- Chronic heart failure
- Myocardial Reinfarction Prevention
Contraindications (13)
- Acute nephropathy
- Bradycardia
- Bronchospasm
- Cardiogenic shock
- Complete atrioventricular block
- Decompensated cardiac failure
- Diabetes mellitus
- Disease of liver
- Hepatic failure
- Hypoglycemic disorder
- Peripheral vascular disease
- Second degree atrioventricular block
- Sick sinus syndrome
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic beta-Antagonists |
|---|---|
| Established pharmacologic class | beta-Adrenergic Blocker |
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-1 adrenergic receptor | ADRB1 | antagonist | Ki 8.50 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 8.00 |
| Beta-2 adrenergic receptor | ADRB2 | antagonist | Ki 7.50 |
| Beta-3 adrenergic receptor | ADRB3 | antagonist | Ki 5.66 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2007-12-17 | FDA | — | FOREST LABS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C07AB12 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective |
C07BB12 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND THIAZIDES › Beta blocking agents, selective, and thiazides |
C07FB12 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS, OTHER COMBINATIONS › Beta blocking agents and calcium channel blockers |
C09BX07 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations |
C09DX05 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs), other combinations |
C10BX22 | CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- FDA label: CYP2D6 · No Clinical PGx
- HCSC label: CYP2D6 · No Clinical PGx
- Swissmedic label: CYP2D6 · Informative PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Acute kidney injury | 699.9 |
| Bradycardia | 468.9 |
| Hyperkalaemia | 328.3 |
| Hypotension | 287.6 |
| Hypertensive crisis | 260.9 |
| Hyponatraemia | 254.2 |
| Drug interaction | 218.5 |
| Anaemia | 210.1 |
| Systemic lupus erythematosus | 203.8 |
| Lactic acidosis | 202.6 |
| Syncope | 199.2 |
| Hypokalaemia | 177.7 |
Chemical structure
| Molecular formula | C22H25F2NO4 |
|---|---|
| Molecular weight | 405.44 g/mol |
| CAS number | 118457-14-0 |
| InChIKey | KOHIRBRYDXPAMZ-UHFFFAOYSA-N |
| PubChem CID | 71301 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Nebivolol used for?
DrugCentral lists the following indications for Nebivolol: Hypertensive disorder.
How does Nebivolol work?
Nebivolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB1 (antagonist), HTR1A, ADRB2 (antagonist) and ADRB3 (antagonist).
When was Nebivolol first approved?
Nebivolol was first approved by the FDA in 2007.
What drug class does Nebivolol belong to?
Nebivolol is in the beta-Adrenergic Blocker class.
What is the chemical formula of Nebivolol?
Nebivolol has the molecular formula C22H25F2NO4 and a molecular weight of 405.44 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1887 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201731 — compound record and bioactivity
- PubChem CID 71301 — chemical identifiers
- DrugBank DB04861 — drug record
- FDA UNII 030Y90569U — substance identity
- DailyMed: FDA labels for Nebivolol — current prescribing information (label search)
- UniProt P08588 (ADRB1) — target protein
- UniProt P08908 (HTR1A) — target protein
- UniProt P07550 (ADRB2) — target protein
- UniProt P13945 (ADRB3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.